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Background:Within the diverse phenotypic spectrumof hypertrophic cardiomyopathy (HCM), subgroups
of patientswith apical hypertrophy (APH),midventricular obstruction (MVO), and apical aneurysm (APA)
have emerged. While previous studies have suggested the existence of considerable overlap between
APH, MVO, and APA, there are still many unanswered questions. Therefore, we attempted to clarify the
relationship of the above three phenotypes of HCM with respect to prevalence, overlap, and outcomes.
Methods: Among the 544 study HCM patients (mean follow-up period: 11.6±7.4 years), 170 with APH
(31.3%), 51 with MVO (9.4%), and 24 with APA (4.4%) were examined.
Results: Therewas phenotypic overlap between APH andMVO in 17 patients, APH and APA in 14 patients,
and MVO and APA in 14 patients. Furthermore, a combination of APH, MVO, and APA was observed in
eight patients. Detailed analysis of the relationship between overlapping phenotypes and the prognosis
showed that APA patients without a history of APH had an extremely poor outcome (probability of the
combined endpoint of sudden death and potentially lethal arrhythmic events ≥50%). Conversely, APH
patients without MVO had a strikingly good outcome (probability of the combined endpoint <5%). Other
patients had an intermediate outcome (probability of the combined endpoint 10–40%).
Conclusions: Our results suggest that overlap between these three forms of HCM is substantial, and that
detailed classiﬁcation of the overlapping phenotypes is clinically meaningful.
4 Jap© 201
ntroduction
Hypertrophic cardiomyopathy (HCM) is a genetic myocardial
isease characterized by marked variability of the morphologi-
al features and natural history [1–6]. Within the diverse clinical
nd phenotypic spectrum of HCM, subgroups of patients charac-
erizedby left ventricular apical hypertrophy (APH),midventricular
bstruction (MVO), andapical aneurysm(APA)haveemerged [7–9].
PH is a speciﬁc variant of HCM, in which myocardial hypertrophy
redominantly affects the left ventricular apical region, resulting
n a spade-shaped left ventricular conﬁguration and giant negative
-waves [7,10–14]. MVO is a relatively rare form of HCM that is
haracterized by a pressure gradient at the midventricular level
nd is unrelated to systolic anterior motion of the mitral valve,
eing caused by contact between the hypertrophic septum and a
ypercontractile left ventricular free wall [9,15]. APA is a rare vari-
nt of HCM, in which there is a thin-walled dyskinetic or akinetic
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segment at the most distal portion of the chamber that has rel-
atively wide communication with the left ventricular cavity [8].
While numerous previous case reports and studies have suggested
the existence of considerable overlap between APH, MVO, and APA
[8,9,12,13,16–23], the clinical courses of the above three forms of
HCM seem to be heterogeneous. Our previous study and a report
by Maron and colleagues have demonstrated a largely unfavorable
clinical course for HCM patients with MVO and/or APA [8,9]. In
contrast, APHpatients typically havemild symptoms, andAPHgen-
erally followsamorebenigncoursewitha lowermortality rate than
other forms of HCM [7,14]. Accordingly, it is our impression that
there are many unanswered questions about the overlap between
these three phenotypes of HCM. Therefore, we attempted to clarify
the relationship between APH, MVO, and APA in a relatively large
HCM cohort, especially with respect to their prevalence, overlap,
clinical course, and outcomes.
MethodsPatients
The study population included 544 patients with a clinical diag-
nosis of HCM who were enrolled from 1980 to 2008 at Tokyo
served.
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MVO and/or APA. A ﬂow diagram summarizing the clinical course
of these 208 HCM patients is shown in Fig. 2. Of the 170 APH
patients, 17 patients were complicated by MVO, and 8 of these
17 APH patients with MVO developed APA formation during the
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Fig. 1. Venn diagram of phenotypic overlap among APH, MVO, and APA in 208
HCM patients with APH and/or MVO and/or APA. There was overlap between APH64 Y. Minami et al. / Journal o
omen’s Medical University Hospital (Tokyo, Japan). The initial
valuation was deﬁned as the ﬁrst clinical assessment at which
n echocardiogram diagnostic of HCM was obtained, while the
ost recent evaluationwas performed in the clinic or by telephone
nterview. Someof thesepatientswere included inapreviouspubli-
ation fromour institution [9], but clinical follow-upswereupdated
rom the timeof completion of the study. This studywas carried out
ccording to the principles of the Declaration of Helsinki, and the
tudy protocolwas approved by our institutional ethics committee.
eﬁnitions
The diagnosis of HCM was based on documentation by two-
imensional echocardiography of a hypertrophic, non-dilated left
entricle in the absence of any other cardiac and/or systemic dis-
ase that could cause similar hypertrophy [1,2].
Left ventricularMVOwas diagnosedwhen both of the following
riteria were satisﬁed: (1) the peak instantaneous midventricular
radientwas estimated tobe≥30mmHg; and (2)midcavitaryoblit-
ration was caused by contact of marked septal hypertrophy with
hypercontractile left ventricular free wall, rather than by systolic
nterior motion of the anterior leaﬂet of the mitral valve [9,15,24].
The diagnostic criteria for APH included asymmetric left ven-
ricular hypertrophy that was conﬁned predominantly to the left
entricular apical region, along with an apical wall thickness
15mm[7]. Left ventricularAPAwasdeﬁnedasa thin-walleddysk-
netic or akinetic segment at the most distal part of the chamber
howing relatively wide communication with the left ventricular
avity [8]. Patients presenting with APH subsequently develop-
ng APA during the follow-up period were considered to have an
verlap between APH and APA. In patients with APA, MVO was
onsidered to be absent when the estimated peak instantaneous
radient was <30mmHg. These patients were thus considered to
ave APA alone.
Documentation of atrial ﬁbrillation was based on electro-
ardiograms recorded either after the onset of symptoms or
uring a routine medical examination in an asymptomatic patient
25]. Ambulatory electrocardiograms covering at least a 24-h
eriod were reviewed in all patients to detect the occurrence of
on-sustainedventricular tachycardia,whichwasdeﬁnedas amin-
mumof three consecutive ventricular beatswith a rate of≥120per
inute [1,2].
The endpoint of this study was the combination of sudden
eath and potentially lethal arrhythmic events, in which unex-
ected death occurred in the absence of or within 1h after the
nset of symptoms in patients with a previously relatively stable
r uneventful course, including thosewhowere successfully resus-
itated after cardiac arrest (ventricular ﬁbrillation or ventricular
achycardia with pulseless collapse) and those with appropriate
mplantable deﬁbrillator interventions [9].
chocardiography
Echocardiographic studies were conducted using commer-
ially available ultrasound equipment. Complete M-mode, two-
imensional, and Doppler studies were performed in the left
ateral decubitus or supine position by the parasternal, apical,
nd subcostal approaches. Color Doppler and pulse-wave Doppler
chocardiography were used to localize the site of left ventricu-
ar obstruction. The peak left ventricular gradient was quantiﬁed
y continuous-wave Doppler echocardiography under resting con-
itions. MVO was deﬁned by the detection of systolic apposition
f the mid-left ventricular walls (and often the papillary muscles),
ith abnormally high velocities persisting through late systole and
ften with early diastolic paradoxical jet ﬂow [26]. When an api-
al acoustic window was difﬁcult to obtain, contrast-enhancediology 64 (2014) 463–469
echocardiography (27 patients) and/or cardiovascular magnetic
resonance (CMR) imaging (55 patients) was done to obtain ade-
quate visualization of the left ventricular apex among 208 patients
with APH and/or MVO and/or APA. Contrast-enhanced echocar-
diography was performed by intravenous injection of 300mg/ml
galactose–palmitic acid (Levovist, Schering, Berlin, Germany) at a
rate of 5ml/5 s.
Cardiovascular magnetic resonance imaging
All CMR studies were performed with a Magnetom Vision 1.5-T
whole body imaging system (Siemens Medical Systems, Erlan-
gen, Germany) from 2001 to July 2003, while a Gyroscan Intera
(PhilipsMedical Systems,Best, TheNetherlands)wasused fromJuly
2003 onward. Breath-holding electrocardiography-gated steady-
state free precession cine images were acquired in 7–10 short-axis
slices and in the 2- and 4-chamber long-axis views.
Statistical analysis
AnalyseswereperformedwithSASsystemver. 9.1 software (SAS
Institute, Cary, NC, USA). Results are presented as the mean± SD
or as frequencies. One-way analysis of variance was used to
compare values among the groups for continuous variables, and
Kruskal–Wallis H-test was used for ordinal variables. A chi-square
or Fisher exact test (when an expected value was <5) was used to
compare nominally scaled variables. A two-tailed p-value of less
than 0.05 was considered to indicate statistical signiﬁcance.
Results
Prevalence, overlap, clinical course, and baseline characteristics
The 544HCMpatients (age at diagnosis: 50.7±15.2 years, 63.6%
men, follow-upperiod: 11.6±7.4 years) included170patientswith
APH (31.3%), 51 patients with MVO (9.4%), and 24 patients with
APA (4.4%). As shown in Fig. 1, the overlap between APH, MVO,
and APA was observed in 208 HCM patients who had APH and/orand MVO in 17 patients (subsets D and E), APH and APA in 14 patients (subsets A
and D), and MVO and APA in 14 patients (subsets D and G). Furthermore, the com-
bination of APH, MVO, and APA was observed in eight patients (subset D). APA,
apical aneurysm; APH, apical hypertrophy; HCM, hypertrophic cardiomyopathy;
MVO, midventricular obstruction.
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Fig. 2. Flow diagram summarizing the clinical course of the 208 HCM patients with
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APH and/or MVO and/or APA. Letters A–G refer to the phenotypic subsets shown
n Fig. 1. APA, apical aneurysm; APH, apical hypertrophy; HCM, hypertrophic car-
iomyopathy; MVO, midventricular obstruction.
ollow-up period. Six of the 153 APH patients without MVO also
eveloped APA. In the 34 MVO patients without APH, 6 patients
ad complicated APA during the follow-up period. The remaining
our APA patients already had APA from the initial clinical assess-
ent atwhich an echocardiogramdiagnostic of HCMwas obtained,
n the absence of APH and MVO. The baseline demographic and
able 1
aseline characteristics of HCM patients with APH, MVO, and/or APA.
Variable APH
(N=170)
Age at diagnosis (years) 51.6±13.8
Male, n (%) 118 (69.4)
Family history of sudden death, n (%) 15 (8.8)
Maximum left ventricular wall thickness (mm) 19.5±3.9
Left atrial dimension (mm) 38.0±8.2
Non-sustained ventricular tachycardia, n (%) 72 (42.4)
Atrial ﬁbrillation, n (%) 43 (25.3)
Unexplained syncope, n (%) 30 (17.6)
NYHA functional class at diagnosis, n (%)
I 100 (58.8)
II 67 (39.4)
III 3 (1.8)
Progressive heart failure, n (%) 13 (7.6)
Stroke, n (%) 13 (7.6)
Follow-up period (years) 11.7±7.2
ata are number (%) or mean± SD.
PA, apical aneurysm; APH, apical hypertrophy; HCM, hypertrophic cardiomyopathy; MViology 64 (2014) 463–469 465
clinical characteristics of patients with APH, MVO, and APA are
shown in Table 1. Since these groups overlapped each other, sta-
tistical analysis was not performed on the data in Table 1. The
mean age of these overlapping patients at diagnosis was about
50 years, andmen comprised a high proportion of the study cohort.
Patients with APA were most likely to have established major risk
factors for sudden death, such as a family history of sudden death,
non-sustained ventricular tachycardia, and unexplained syncope.
In addition, the baseline New York Heart Association (NYHA) func-
tional class was the highest and progressive heart failure was most
common in patients with APA. In contrast, patients with APH were
least likely to have a family history of sudden death, syncope,
and heart failure. On the other hand, stroke was most common
in patients with MVO. Maximum left ventricular wall thickness
and left atrial dimension were the greatest in patients with APA,
although the differences among the groups were small.
Detailed analysis of overlapping phenotypes and outcomes
Twenty out of 208 HCM patients who had APH and/or MVO
and/or APA (9.6%) suffered from the combined endpoint of sud-
den death and potentially lethal arrhythmic events, including
6 patients with sudden death, 10 patients who were successfully
resuscitated after cardiac arrest, and 4 patients with appropri-
ate implantable deﬁbrillator interventions, over a mean follow-up
period of 11.6±7.4 years. The probability of the combined end-
point in patients with each subset of the overlapping phenotypes
is shown in Fig. 3. The worst outcome was seen in patients who
had both MVO and APA without APH (subset G in Figs. 1–3); ﬁve
out of six patients in this subset (83.3%) experienced the combined
endpoint. The second worst subset was patients who only had APA
(subset F in Figs. 1–3); two out of four patients (50.0%) experienced
sudden death and potentially lethal arrhythmic events. Represen-
tative echocardiographic and CMR ﬁndings of the patients with
subsets F and G are shown in Fig. 4. In contrast, no events occurred
in patients who had both APH and APA without MVO (subset A
in Figs. 1–3). Patients with APH alone (subset B in Figs. 1–3) also
had a benign clinical course, and only 4.1% experienced the com-
bined endpoint. In summary, APA patients without a history of
APH (subsets F and G in Figs. 1–3) had a poor long-term outcome
among those with overlapping phenotypes of HCM (probability of
the combined endpoint ≥50%). Conversely, APH patients without
MVO (subsets A and B in Figs. 1–3) had a strikingly good clinical
course (probability of the combined endpoint <5%). Other subsets
of the overlapping phenotypes (subsets C, D, and E in Figs. 1–3) had
intermediate probabilities of the combined endpoint (10.7%, 12.5%,
MVO APA
(N=51) (N=24)
53.5±15.0 52.8±14.4
31 (60.8) 16 (66.7)
6 (11.8) 5 (20.8)
19.4±4.9 20.3±4.3
40.5±5.8 40.7±5.7
18 (35.3) 14 (58.3)
13 (25.5) 6 (25.0)
12 (23.5) 8 (33.3)
13 (25.5) 6 (25.0)
36 (70.6) 14 (58.3)
2 (3.9) 4 (16.7)
6 (11.8) 4 (16.7)
6 (11.8) 2 (8.3)
9.7±8.1 9.9±8.7
O, midventricular obstruction; NYHA, New York Heart Association.
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Fig. 3. Probability of the combined endpoint of sudden death and potentially lethal arrhythmic events for patients from each overlapping phenotypic subset of HCM. Letters
A–G refer to the phenotypic subsets shown in Figs. 1 and 2. A detailed analysis of the relationship between the prognosis and overlapping phenotypes of APH, MVO, and
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dPA showed that the outcomes were extremely heterogeneous. APA, apical aneury
bstruction.
nd 33.3%, respectively). The baseline demographic and clinical
haracteristics of the study population according to the prognostic
ubsets are shown in Table 2. The baseline NYHA functional class
as the highest in patients with subset F and G. On the other hand,
he left atrial dimensionwas the largest in patientswith subset C, D,
nd E. However, there were no statistically signiﬁcant differences
ith respect to established major risk factors for sudden death
a family history of sudden death, severe left ventricular hyper-
rophy, non-sustained ventricular tachycardia, and unexplained
yncope) among the groups.
iscussion
In thepresent study,we conﬁrmed the existence of considerable
verlap between APH, MVO, and APA, as has been suggested by
umerous previous case reports and studies. Detailed analysis of
he relationship between these overlapping phenotypes and the
rognosis showed that the outcomes of patients were extremely
eterogeneous. APH patients without MVO had a good long-term
utcome, with a low risk of sudden death and potentially lethal
rrhythmic events. In contrast, APA patients without a history of
PH had an extremely poor outcome in our study cohort.
Numerous previous case reports and studies have sug-
ested the existence of overlap between APH, MVO, and APA
8,9,12,13,16–23]. APH has often been complicated by MVO in
revious case reports and studies [9,13,18,20,23]. Eriksson and col-
eagues [7] reported that patients with APH could be divided into
wo groups, depending on whether they had isolated asymmet-
ic APH (“pure” form) or had coexisting hypertrophy of the mid
nter-ventricular septum (“mixed” form). Although themechanism
y which MVO complicates APH is unknown, it is possible that
he “mixed” form with marked mid-septal hypertrophy might be
esponsible for this association [13]. Indeed, 4 out of 29 (13.8%)
atients with “mixed” APHwere complicated byMVO in the report
y Kubo and colleagues [13]. The combination of APH and APA
as also been described in numerous studies and case reports
12,13,18–20]. In a previous study, apical myocardial infarction
espitenormal coronary arterieswas found inabout10%ofpatientsH, apical hypertrophy; HCM, hypertrophic cardiomyopathy; MVO, midventricular
with APH [7]. The mechanisms responsible for apical ischemia and
aneurysm in APH are still unclear, although there is some evi-
dence that limitation of the coronary ﬂow reserve may be involved
[10]. A reduced capillary myocardial ratio, small vessel disease,
and other factors may also cause regional apical ischemia and lead
to the development of apical infarction and APA [27,28]. Previous
case reports and studies have indicated that MVO is likely to com-
plicate APA in patients with HCM [8,9,16–18,20–22]. Figali and
colleagues [29] reported that patients with the MVO variant of
HCM are at a higher risk of developing left ventricular hypokinesia
or APA formation. In addition, Maron and colleagues [8] hypoth-
esized that the left ventricular APA and the associated regional
myocardial scaring occur secondary to increased left ventricular
wall stress resulting from MVO and the elevation of the intracav-
itary pressure. Increased wall stress imposes a greater pressure
load on the apical myocardium and increases its oxygen demand,
while simultaneously reducing coronary ﬂow through extravascu-
lar compression, leading to chronic myocardial ischemia, scarring,
andAPA formation [8]. Consistentwith numerous previous reports,
our results supported the existence of overlap between these three
phenotypes of HCM (APH, MVO, and APA), and we also obtained
novel epidemiological information about such overlap in a rela-
tively large cohort.
Previous studies have indicated that HCM patients with APH
have a low cardiovascular mortality rate and a good prognosis
[7,14]. In contrast, MVO and APA are commonly associated with an
adverse long-termclinical outcome [8,9]. Furthermore, ourdetailed
analysis of the relationship between overlapping phenotypes and
the prognosis provided some novel prognostic information. In our
analysis, APH patients with MVO tended to have a worse clini-
cal outcome than those without MVO. As mentioned previously,
it is possible that the “mixed” form of APH with marked mid-left
ventricular hypertrophy might be responsible for the association
of APH and MVO [13]. In addition, the cardiovascular event rate
of patients with the “mixed” form of APH is higher than that
of patients with the “pure” form [13,14]. Therefore, it is clini-
cally meaningful to distinguish between these phenotypes of HCM
patients with APH, because APH patients with MVO (and/or the
Y. Minami et al. / Journal of Cardiology 64 (2014) 463–469 467
Fig. 4. Representative echocardiographic andCMR images. (A–C) Echocardiographic imagesof a49-year-oldHCMpatientwhohadonlyAPA (patientwith subset F in Figs. 1–3).
(A) Left ventricular apical 4-chamberviews inend-diastoleandend-systoledemonstratingAPA formation (arrowheads). (B)Parasternal long-axisview inend-diastole showing
asymmetrical basal septal hypertrophy (thin arrow). (C) Although pulse-wave Doppler of the mid ventricle demonstrates systolic and early diastolic paradoxical jet ﬂow,
midventricular gradient was estimated to be far less than 30mmHg. (D–G) Echocardiographic and CMR images of a 69-year-old HCM patient who had both MVO and APA
w 4-cha
A g asy
t peak
a , hyp
“
t
o
bithout APH (patient with subset G in Figs. 1–3). (D and E) Left ventricular long-axis
PA formation (arrowheads). (F) Parasternal long-axis view in end-diastole showin
he mid ventricle demonstrates systolic and early diastolic paradoxical jet ﬂow, and
neurysm; APH, apical hypertrophy; CMR, cardiovascular magnetic resonance; HCMmixed” form) suffer from signiﬁcantlymore cardiovascular events
han APH patients without MVO (and/or the “pure” form). On the
ther hand, APA patients with a history of APH tended to have a
etter prognosis than those without a history of APH in this study.mber CMR cine images in end-diastole and end-systole demonstratingMVO (*) and
mmetrical basal septal hypertrophy (thin arrow). (G) Continuous-wave Doppler of
midventricular gradient was estimated to be 60.5mmHg (thick arrow). APA, apical
ertrophic cardiomyopathy; MVO, midventricular obstruction.Binder and colleagues [11] likewise reported that apical outpouch-
ing does not appear to result in higher complication rates among
patients with APH. The results of this study, as well as those of
Binder and colleagues, suggest that HCM patients with APH may
468 Y. Minami et al. / Journal of Cardiology 64 (2014) 463–469
Table 2
Baseline characteristics of HCM patients with APH, MVO, and/or APA according to the prognostic subsets in Figs. 1–3.
Variable Subsets A and B Subsets C, D, and E Subsets F and G p-Value
(N=153) (N=45) (N=10)
Age at diagnosis (years) 52.0±13.7 53.6±15.6 56.7±13.6 0.498
Male, n (%) 109 (71.2) 26 (57.8) 6 (60.0) 0.204
Family history of sudden death, n (%) 12 (7.8) 5 (11.1) 2 (20.0) 0.379
Maximum left ventricular wall thickness (mm) 19.3±3.8 19.4±4.9 20.7±5.0 0.598
Left atrial dimension (mm) 37.4±8.2 40.8±6.1 39.9±6.4 0.032
Non-sustained ventricular tachycardia, n (%) 62 (40.5) 16 (35.6) 4 (40.0) 0.835
Atrial ﬁbrillation, n (%) 38 (24.8) 12 (26.7) 2 (20.0) 0.904
Unexplained syncope, n (%) 22 (14.4) 10 (22.2) 2 (20.0) 0.435
NYHA functional class at diagnosis, n (%) <0.001
I 95 (62.1) 13 (28.9) 0 (0.0)
II 56 (36.6) 30 (66.7) 7 (70.0)
III 2 (1.3) 2 (4.4) 3 (30.0)
Progressive heart failure, n (%) 11 (7.2) 6 (13.3) 2 (20.0) 0.215
Stroke, n (%) 12 (7.8) 5 (11.1) 1 (10.0) 0.781
Follow-up period (years) 11.5±7.0 10.5±8.1 6.2±8.0 0.074
D
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PA, apical aneurysm; APH, apical hypertrophy; HCM, hypertrophic cardiomyopath
epresent a genetically unique population with a benign clinical
ourse. Although highly speculative, it is possible to hypothesize
hat two different mechanisms of APA formation (i.e. apical infarc-
ion due to APH vs. apical scarring due to MVO and increased wall
tress) have differing inﬂuences on the prognosis of overlapping
CM phenotypes. Thus, history taking should focus on the pres-
nce or absence of APH in patients with APA, and the treatment of
PA patients without a history of APH may be modiﬁed to include
rimary prevention of sudden death by implanting a deﬁbrillator
8]. Our results suggest that detailed classiﬁcationof the three over-
apping phenotypes of HCM can be clinically useful, and also raise
ovel considerations with regard to the treatment because clinical
nd prognostic features differ greatly among the subsets, as shown
n Fig. 3.
Recently, Olivotto and colleagues [30] proposed a simple frame-
ork for systematic clinical staging of the disease progression in
CM patients: these are deﬁned as non-hypertrophic HCM, clas-
ic phenotype, adverse remodeling, and overt dysfunction [30]. Of
hese, adverse remodeling is deﬁnedby thepresenceof unfavorable
tructural modiﬁcations, superimposed to the classic phenotype,
ranslating into increasing left ventricular ﬁbrosis and worsening
unction, such as diastolic dysfunction, marked atrial dilatation,
rrhythmias, and APA formation [30]. As shown in Figs. 2 and 3, our
esults may represent the adverse remodeling process in the group
f 208HCMpatientswithAPHand/orMVOand/orAPA, fromclassic
PH phenotype to adverse APA remodeling, especially in patients
omplicated by MVO. We hope that our ﬁndings will lead to better
ecognition of the adverse remodeling process and prognostic het-
rogeneity of HCM patients with APH and/or MVO and/or APA, and
ead to the adoption of improved therapeutic strategies for these
atients with overlapping phenotypes who are often difﬁcult to
anage. This remains an important area of future research.
imitations
This studywasbasedon the retrospective enrollmentof patients
ithHCM,which is anunavoidable limitation sharedbyvirtually all
arge-scale studies of this condition. In addition, this studywas con-
ucted at a single tertiary referral center in Japan andwas therefore
ubject to selection bias because it was based on a highly selected
opulationofHCMpatients. Furthermore, identiﬁcationofAPHand
PAwasmainly based on transthoracic echocardiography,which is
ess reliable for detecting these conditions than contrast-enhanced
chocardiography and CMR imaging. Because contrast-enhanced
chocardiography and CMR were not performed on all patients in
his study,weare likely tohaveunderestimated the trueprevalenceO, midventricular obstruction; NYHA, New York Heart Association.
of APH and APA, and we could not examine the detailed mor-
phologic presentation of APH (“pure” form or “mixed” form), and
clarify whether there are differences between subtypes of APH in
terms of developing to MVO and/or APA formation in our cohort of
HCM patients. Finally, genetic screening was not performed in the
present study. Genome-wide association studies and gene expres-
sion proﬁling are needed to achieve better understanding of the
genetic background behind phenotypic overlap in HCM patients.
Conclusions
We attempted to clarify the relationship among APH, MVO, and
APA within a single center HCM cohort. As a result, this study con-
ﬁrmedtheexistenceofoverlapamongAPH,MVO,andAPA.Detailed
analysis of the relationship between overlapping phenotypes and
the prognosis showed that the outcomes were extremely hetero-
geneous. In contrast to the benign clinical course of APH patients
(especially thosewithoutMVO), patientswithMVOandAPA (espe-
cially APA without a history of APH) had an unfavorable outcome.
We hope that this report will lead to better recognition of the
adverse remodeling process and prognostic heterogeneity demon-
strated by HCM patients with these overlapping phenotypes, as
well as to adoption of improved therapeutic strategies.
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